CELLTRION's major therapeutics are expanding their market influence as they continue to succeed in public institution bids in Latin American regions such as Peru.
On the 15th, CELLTRION announced that its biosimilar Truxima (generic name Rituximab) 500 mg, used for treating blood cancer and autoimmune diseases, won the bid at the Ministry of Health (CENARES), the largest public institution market in Peru. Additionally, Truxima 100 mg also won the bid at the Workers' Insurance Fund. With this successful contract, CELLTRION will supply Truxima 500 mg to the Ministry of Health twice and provide Truxima 100 mg to the Workers' Insurance Fund for one year starting this month. It is explained that through these two contracts alone, CELLTRION has secured more than 50% of the Rituximab market in Peru.
In the Workers' Insurance Fund bid, the anticancer biosimilar Herzuma (generic name Trastuzumab), used for treating breast and stomach cancers, and the autoimmune disease treatment biosimilar Yuflyma (generic name Adalimumab) were also awarded. The Herzuma bid represents the largest volume, accounting for 53% of the Trastuzumab market in Peru, with supply planned for one year starting this month. The Yuflyma contract is known to cover approximately 20% of the Adalimumab market in Peru.
It is explained that CELLTRION’s positive bidding results in the Peruvian public institution market were largely due to the market-tailored strategies of its local subsidiary. CELLTRION Peru analyzed various factors comprehensively, including prices, volumes, and supply trends of products that had won bids in recent years, and pursued an optimized strategy. Furthermore, as Peruvian regulatory authorities have recently enforced strict management of drug quality and supply stability, trust in the company and its products has steadily increased, supported by CELLTRION’s abundant global prescription data and the fact that there have been no product supply issues.
CELLTRION plans to launch RamcimaSC, the world’s only subcutaneous (SC) formulation of an infliximab-based autoimmune disease treatment, and Vegzelma, an anticancer biosimilar used for treating colorectal and non-small cell lung cancers, in the Peruvian market within this year.
Kang Kyung-doo, head of CELLTRION’s Latin America region, said, “We were able to achieve good results through thorough analysis of the local healthcare market and close networks with government agencies. With upcoming events such as product launches and bid participations across Latin America this year, we will strengthen marketing activities to expand the success achieved in Peru to neighboring countries.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
